DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

Information source: Ludwig-Maximilians - University of Munich
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia

Intervention: IBZM-SPECT (bolus and constant infusion paradigm) (Procedure)

Phase: N/A

Status: Completed

Sponsored by: Ludwig-Maximilians - University of Munich

Official(s) and/or principal investigator(s):
Oliver Pogarell, MD, Principal Investigator, Affiliation: Dept. of Psychiatry, University of Munich
Klaus Tatsch, MD, Principal Investigator, Affiliation: Dept. of Nuclear Medicine, University of Munich


This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.

Clinical Details

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Primary outcome: dopamine receptor availability


Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.


Inclusion Criteria:

- Clinical diagnosis of schizophrenia (currently unmedicated)

- Subjects at risk for the development of schizophrenia (prodromal symptoms)

- Healthy subjects

- Written informed consent

Exclusion Criteria:

- Neurological or severe somatic disorders

- Women during pregnancy or lactation

- Occupational exposition to radiation > 15mSv

- Medication known to interfere with IBZM

- Contraindications for the use of amphetamine challenge

Locations and Contacts

Dept. of Nuclear Medicine, Munich D-81377, Germany

Dept. of Psychiatry, Munich D-80336, Germany

Additional Information

Starting date: January 2004
Last updated: May 6, 2008

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017